<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786836</url>
  </required_header>
  <id_info>
    <org_study_id>STU 122015-008</org_study_id>
    <secondary_id>U01DK058369</secondary_id>
    <nct_id>NCT02786836</nct_id>
  </id_info>
  <brief_title>13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF</brief_title>
  <acronym>ALFSG-MBT</acronym>
  <official_title>13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ALFSG-MBT protocol is for a multicenter, open label, non-randomized study to determine&#xD;
      the value of Breath Identification® (BreathID®) N-(4-Methoxy-13C-phenyl)acetamide&#xD;
      (13C-Methacetin) Breath Test System in predicting the outcome of patients diagnosed with&#xD;
      severe acute liver injury that is not related to acetaminophen overdose or acute liver&#xD;
      failure who meet inclusion/exclusion criteria.&#xD;
&#xD;
      Up to 200 evaluable patients will be enrolled. An evaluable patient is one who has completed&#xD;
      one or more breath tests for at least 30 minutes after administration of the 13C-Methacetin&#xD;
      solution (test substrate).&#xD;
&#xD;
      The Breath Test will be performed up to five times during the study period on all enrolled&#xD;
      patients. The first Breath Test will be performed upon admission into the study (Day 1) and&#xD;
      repeated on Days 2, 3, 5 and 7 provided no contra-indications are present. Each test&#xD;
      continuously measures changes in the metabolism of the 13C-Methacetin in order to assess the&#xD;
      improvement or deterioration in liver metabolic function about improvement or deterioration&#xD;
      in liver metabolic function. If an enrolled non-APAP ALI or ALF patient receives a liver&#xD;
      transplant, is discharged /transferred from the hospital or dies prior to Day 7, additional&#xD;
      Breath Tests will not be performed.&#xD;
&#xD;
      Patients will be contacted for the Day 21 follow up (21 days after enrollment into the trial)&#xD;
      to determine spontaneous survival, transplantation and occurrence of serious adverse events&#xD;
      since the patient's last study treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The importance of identifying the patient with with ALI or ALF who is likely to die without a&#xD;
      liver transplant cannot be overstated and has remained a primary focus of clinical&#xD;
      investigation for 25 years. A recent analysis also conducted by the Acute Liver Failure Study&#xD;
      Group (ALFSG) found that poor outcomes in the ALI patients are less frequent than is observed&#xD;
      in the ALF population. However, in cases where ALI was not related to an acetaminophen (APAP)&#xD;
      overdose, progression to poor outcomes was similar. Traditional scoring systems and&#xD;
      prognostic models, such as King's College Criteria (KCC), Sequential Organ Failure Assessment&#xD;
      (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II), currently used to&#xD;
      monitor patients with ALF lack individual sensitivity and specificity and do not provide&#xD;
      direct information about the liver's metabolic function, which is a key variable in assessing&#xD;
      liver status and potential disease progression versus recovery in ALF patients. Despite&#xD;
      recent advances used by the ALFSG Prognostic Index (ALFSG-PI), ALI Prognostic Index (ALI-PI)&#xD;
      and Model for End-Stage Liver Disease (MELD), better predictive modalities are still needed.&#xD;
&#xD;
      The 13C-Methacetin breath test is a rapid, reproducible, point-of-care test of liver&#xD;
      metabolic function. After oral or naso-enteric/orogastric tube administration, the 13C&#xD;
      labeled Methacetin is O-demethylated by cytochrome P450 1A2 (liver enzyme name) in the liver&#xD;
      and further biotransformed into carbon dioxide labeled with carbon 13 (13CO2), which is&#xD;
      expired in breath. The BreathID® Molecular Correlation Spectroscopy (MCS) device captures and&#xD;
      quantifies expired 13CO2 and standardizes recovery against expired normal carbon dioxide&#xD;
      (12CO2) through a nasal cannula (in conscious patients) or an adaptor connected to the&#xD;
      ventilator line (for intubated patients). The results obtained from the device are expressed&#xD;
      as delta over baseline (DOB), which expresses the change in 13CO2/12CO2 ratio in comparison&#xD;
      to the baseline measurement. It can be transformed into the percentage of 13C dose recovered&#xD;
      over time (PDR) after the ingestion of Methacetin, and the cumulative PDR (CPDR), the rate at&#xD;
      which 13C substrate is metabolized, derived from the breath 13C/12C ratio.&#xD;
&#xD;
      This is a multicenter, open label, non-randomized study of the MBT to assess functional&#xD;
      trends of liver metabolism in patients diagnosed with severe acute liver injury not related&#xD;
      to acetaminophen overdose (non-APAP ALI) or acute liver failure (ALF). Up to 200 evaluable&#xD;
      patients with non-APAP ALI or ALF present at the time of enrollment into the ALFSG Registry&#xD;
      will be consecutively enrolled. An evaluable patient is one who has completed one or more&#xD;
      Breath Tests measured for a minimum of 30 (and ideally 60) minutes after administration of&#xD;
      the 13C-Methacetin solution. Study sites will include up to 11 of the clinical sites located&#xD;
      in the United States that are involved in the ALFSG.&#xD;
&#xD;
      The Breath Test will be performed up to five times during the study period on all enrolled&#xD;
      subjects. The first Breath Test will be performed as close to the time of study enrollment as&#xD;
      possible upon admission into the study (Day 1). The Breath Test will be repeated on Days 2,&#xD;
      3, 5 and 7 as close as possible to the same time of day as the first Breath Test. If a&#xD;
      subject who is enrolled into the ALFSG-MBT Trial with non-APAP ALI converts to ALF, breath&#xD;
      test collection will continue until a maximum of five Breath Tests have been performed. If an&#xD;
      enrolled non-APAP ALI or ALF subject receives a liver transplant, is discharged/transferred&#xD;
      from the hospital or dies prior to Day 7, no additional Breath Tests will be performed.&#xD;
      Enrolled patients will be contacted for the Day 21 follow up (21 days after the subject's&#xD;
      enrollment into the trial) to determine spontaneous survival, transplantation and occurrence&#xD;
      of serious adverse events since the subject's last study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2016</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Percent Dose Recovery (PDR) Value</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Percent Dose Recovery (PDR) Value</measure>
    <time_frame>The first MBT reading either on Day 1 or Day 2 and Day 21</time_frame>
    <description>This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percent Dose Recovery 20 (cPDR20) Value</measure>
    <time_frame>The first MBT reading either on Day 1 or Day 2 and Day 21</time_frame>
    <description>The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Acute Liver Failure</condition>
  <arm_group>
    <arm_group_label>13C-Methacetin Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled into the ALFSG Registry with the duration of illness &lt;26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C-Methacetin</intervention_name>
    <description>The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.&#xD;
The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate.</description>
    <arm_group_label>13C-Methacetin Testing</arm_group_label>
    <other_name>N-(4)-13Cmethoxyphenyl acetamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult men or women (18-80 years of age)&#xD;
&#xD;
          2. Severe acute liver injury not related to acetaminophen overdose: INR ≥2.0; no evidence&#xD;
             of HE&#xD;
&#xD;
          3. Acute liver failure: INR ≥1.5; presence of any degree of HE&#xD;
&#xD;
          4. Duration of illness &lt;26 weeks&#xD;
&#xD;
          5. Enrolled into the ALFSG Registry.&#xD;
&#xD;
          6. Written informed consent from the patient or patient's legally authorized&#xD;
             representative or family member as defined in the Federal Register Number 21&#xD;
             Congressional Federal Register (CFR)50.3(m)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of pre-existing chronic liver disease&#xD;
&#xD;
          2. Pre-existing New York Heart Association stage III/IV heart failure&#xD;
&#xD;
          3. Evidence of pre-existing chronic renal failure&#xD;
&#xD;
          4. Chronic hemodialysis prior to hospital admission&#xD;
&#xD;
          5. Evidence of cirrhosis (unless clinically acute Wilson disease or autoimmune non-APAP&#xD;
             ALI or ALF)&#xD;
&#xD;
          6. Severe obstructive lung disease (FEV1 &lt;50% of predicted on previous spirometry)&#xD;
&#xD;
          7. Severe shock, defined as mean arterial pressure (MAP) &lt;70 mmHg despite &gt;15 µg/kg/min&#xD;
             dopamine, &gt;0.1 µg/kg/min epinephrine, or &gt;0.1 norepinephrine µg/kg/min&#xD;
&#xD;
          8. Extensive small bowel resection (&gt;50 cm)&#xD;
&#xD;
          9. Any evidence of upper GI bleeding at enrollment requiring intervention (endoscopy or&#xD;
             red blood cell (RBC) transfusion specifically for upper GI bleeding)&#xD;
&#xD;
         10. Liver transplantation (LT) prior to enrollment. (Note: Listing for LT does not&#xD;
             preclude participation in the trial.)&#xD;
&#xD;
         11. Pregnancy or breastfeeding women (Note: Pregnancy related non-APAP ALI or ALF may be&#xD;
             considered for entry following the delivery of the baby and assuming the mother does&#xD;
             not wish to breastfeed or collect breast milk during the study period.)&#xD;
&#xD;
         12. Allergic to acetaminophen (such as Tylenol® or any other acetaminophen-containing&#xD;
             medications)&#xD;
&#xD;
         13. Participation in other clinical studies evaluating other experimental treatments or&#xD;
             procedures. (Note: Participation in observatory studies is not an exclusion.)&#xD;
&#xD;
         14. Patients in whom enteral drugs or fluids are contra-indicated or the patient either&#xD;
             does not have an appropriately placed naso-enteric/orogastric tube in situ or cannot&#xD;
             tolerate taking the drug preparation orally (200 ml)&#xD;
&#xD;
         15. Budd-Chiari Syndrome&#xD;
&#xD;
         16. Non-APAP ALI or ALF caused by malignancy&#xD;
&#xD;
         17. Moderate and severe adult respiratory distress syndrome (ARDS), as defined by Berlin&#xD;
             Criteria.&#xD;
&#xD;
         18. Subjects who have received amiodarone in the 30 days prior to study enrollment&#xD;
&#xD;
         19. Consumption of any food or beverage that contains caffeine in the 24 hours prior to&#xD;
             enrollment&#xD;
&#xD;
         20. Consumption of any of the following drugs that may interfere with the metabolism of&#xD;
             13C-Methacetin in the 48 hours prior to study enrollment including: allopurinol,&#xD;
             carbamazepine, cimetidine, ciprofloxacin, daidzein, disulfiram, Echinacea, enoxacin,&#xD;
             fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine,&#xD;
             phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil,&#xD;
             zileuton or oral contraceptives&#xD;
&#xD;
         21. Consumption of alcohol in the 24 hours prior to enrollment&#xD;
&#xD;
         22. Smoking cigarettes in the 8 hours prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Fontana, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.utsouthwestern.edu/labs/acute-liver/</url>
    <description>Acute Liver Failure Study Website</description>
  </link>
  <reference>
    <citation>O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989 Aug;97(2):439-45.</citation>
    <PMID>2490426</PMID>
  </reference>
  <reference>
    <citation>Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G, Shaw S, Burroughs AK. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther. 2006 Apr 1;23(7):883-93.</citation>
    <PMID>16573791</PMID>
  </reference>
  <reference>
    <citation>Craig DG, Ford AC, Hayes PC, Simpson KJ. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Ther. 2010 May;31(10):1064-76. doi: 10.1111/j.1365-2036.2010.04279.x. Epub 2010 Feb 24. Review.</citation>
    <PMID>20180786</PMID>
  </reference>
  <reference>
    <citation>Stravitz RT, Reuben A, Mizrahi M, Lalazar G, Brown K, Gordon SC, Ilan Y, Sanyal A. Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. J Hepatol. 2015 Dec;63(6):1345-51. doi: 10.1016/j.jhep.2015.07.021. Epub 2015 Jul 26.</citation>
    <PMID>26220750</PMID>
  </reference>
  <reference>
    <citation>Lalazar G, Adar T, Ilan Y. Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial. World J Gastroenterol. 2009 Feb 28;15(8):966-72.</citation>
    <PMID>19248196</PMID>
  </reference>
  <reference>
    <citation>Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Aliment Pharmacol Ther. 2007 Jul 15;26(2):305-11.</citation>
    <PMID>17593076</PMID>
  </reference>
  <reference>
    <citation>Nista EC, Fini L, Armuzzi A, Candelli M, Zocco MA, Cazzato IA, Merra G, Finizio R, Miele L, Grieco A, Gasbarrini G, Gasbarrini A. 13C-breath tests in the study of microsomal liver function. Eur Rev Med Pharmacol Sci. 2004 Jan-Feb;8(1):33-46. Review.</citation>
    <PMID>15209153</PMID>
  </reference>
  <reference>
    <citation>Starmer GA, McLean S, Thomas J. Analgesic potency and acute toxicity of substituted anilides and benzamides. Toxicol Appl Pharmacol. 1971 May;19(1):20-8.</citation>
    <PMID>5570565</PMID>
  </reference>
  <reference>
    <citation>de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000 Nov;33(5):846-52.</citation>
    <PMID>11097497</PMID>
  </reference>
  <reference>
    <citation>Lalazar G, Pappo O, Hershcovici T, Hadjaj T, Shubi M, Ohana H, Hemed N, Ilan Y. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat. 2008 Oct;15(10):716-28. doi: 10.1111/j.1365-2893.2008.01007.x. Epub 2008 Jul 11.</citation>
    <PMID>18638013</PMID>
  </reference>
  <reference>
    <citation>Lalazar G, Mullhaupt, B., Margalit M. Point of care non-invasive 13C methacetin breath testing accurately identifies significant liver inflammation and fibrosis: a novel method for assessing liver damage. Gastroenterology; 2007 abstract</citation>
  </reference>
  <reference>
    <citation>Allman K, Wilson I. Oxford Handbook of Anaesthesia. 2nd ed. New York: Oxford University Press 2006;xxiv:1203.</citation>
  </reference>
  <reference>
    <citation>Lee WM, James L, Wendon J, Stravitz RT, Pop OT, Audimoolam VK. Does Methacetin breath testing increase acetaminophen hepatotoxicity in the setting of acute liver failure? Hepatology 2015: Accepted for poster presentation at the AASLD Liver Meeting held in San Francisco from November 13-17, 2015.</citation>
  </reference>
  <reference>
    <citation>Audimoolam VK, Patel VC, Bernal W, Meir M, Lalazar G, Ilan Y, Wendon J. Use of an on-line at the point of care 13C-methacetin breath test as an adjunct tool for decision making in patients with acute liver failure. Hepatology 56;4Suppl:970A.</citation>
  </reference>
  <reference>
    <citation>Koch DG, Battenhouse H, Durkalski V, Lee WM, Reuben A. Clinical predictors of spontaneous survival in acute liver failure (ALF) patients with advanced coma. Hepatology 56;4Suppl:964A.</citation>
  </reference>
  <reference>
    <citation>Koch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, Stravitz RT, Larson AM, Liou I, Fix O, Schilsky ML, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Brown RS, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hanje AJ, Olson J, Subramanian RM, Karvellas C, Hameed B, Sherker AH, Lee WM, Reuben A. The Natural History of Severe Acute Liver Injury. Am J Gastroenterol. 2017 Sep;112(9):1389-1396. doi: 10.1038/ajg.2017.98. Epub 2017 Apr 25.</citation>
    <PMID>28440304</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>November 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>William Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute liver failure</keyword>
  <keyword>methacetin</keyword>
  <keyword>breath test</keyword>
  <keyword>severe acute liver injury</keyword>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>ALFSG Registry</keyword>
  <keyword>acetaminophen toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data for the overall study will be shared once the study is completed.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02786836/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with acute liver failure (ALF) who were enrolled into the ALF Study Group Registry at 11 participating investigative U.S. sites were screened for eligibility. In March 2018, patients with acute liver injury (ALI) not related to acetaminophen overdose (APAP) and enrolled into the ALFSG Registry were included and screened for eligibility.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>13C-Methacetin Breath Test (MBT)</title>
          <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® molecular correlation spectrometry (MCS) device. After completion of the baseline segment, one 75 milligram (mg) dose of 13C-Methacetin (test substrate) mixed into 150 milliliters (ml) of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 (carbon-13 dioxide) over a period of up to 60 minutes. A maximum of 5 daily tests were administered on study days 1, 2, 3, 5 and 7 for up to 1 hour after test substrate administration. Patients were contacted 21 days following study enrollment to determine vital status and to check for the development of serious adverse events.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible Patients Enrolled Into the Stud</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device or Pharmacy Issues</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible patients enrolled into the study with at least one 13C-MBT measured for a minimum of 30 minutes after ingestion of the 13C-Methacetin solution.</population>
      <group_list>
        <group group_id="B1">
          <title>13C-Methacetin Breath Test (MBT)</title>
          <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® MCS device. After completion of the baseline segment, one 75 mg dose of 13C-Methacetin (test substrate) mixed into 150 ml of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 over a period of up to 60 minutes. A maximum of 5 daily tests were administered on study days 1, 2, 3, 5 and 7 for up to 1 hour after test substrate administration. Patients were contacted 21 days following study enrollment to determine vital status and to check for the development of serious adverse events.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="28" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Day 1 MBT measured for a minimum of 30 minutes after ingestion of the 13C-Methacetin solution</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Percent Dose Recovery (PDR) Value</title>
        <description>Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>Eligible patients enrolled into the study with available Day 1 13C-MBT results and 21-day outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>13C-Methacetin Breath Test (MBT)</title>
            <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® MCS device. After completion of the baseline segment, one 75 mg dose of 13C-Methacetin (test substrate) mixed into 150 ml of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 over a period of up to 60 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Percent Dose Recovery (PDR) Value</title>
          <description>Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21.</description>
          <population>Eligible patients enrolled into the study with available Day 1 13C-MBT results and 21-day outcome.</population>
          <units>percentage per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Peak PDR for TFS subjects at Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Peak PDR for non-TFS subjects at Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Percent Dose Recovery (PDR) Value</title>
        <description>This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21.</description>
        <time_frame>The first MBT reading either on Day 1 or Day 2 and Day 21</time_frame>
        <population>Eligible patients enrolled into the study with available Day 1 or Day 2 13C-MBT results and 21-day outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>13C-Methacetin Breath Test (MBT)</title>
            <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® MCS device. After completion of the baseline segment, one 75 mg dose of 13C-Methacetin (test substrate) mixed into 150 ml of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 over a period of up to 60 minutes. A maximum of 5 daily tests were administered on study days 1, 2, 3, 5 and 7 up to 1 hour after test substrate administration. Patients were contacted 21 days following study enrollment to determine vital status and to check for the development of serious adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Percent Dose Recovery (PDR) Value</title>
          <description>This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21.</description>
          <population>Eligible patients enrolled into the study with available Day 1 or Day 2 13C-MBT results and 21-day outcome.</population>
          <units>percentage per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 or 2 MBT &amp; Day 21 TFS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 or 2 MBT &amp; Day 21 non-TFS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percent Dose Recovery 20 (cPDR20) Value</title>
        <description>The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21.</description>
        <time_frame>The first MBT reading either on Day 1 or Day 2 and Day 21</time_frame>
        <population>Eligible patients enrolled into the study with the initial 13C-MBT conducted on Day 1 or Day 2, and 21 day outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>13C-Methacetin Breath Test (MBT)</title>
            <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® MCS device. After completion of the baseline segment, one 75 mg dose of 13C-Methacetin (test substrate) mixed into 150 ml of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 over a period of up to 60 minutes. A maximum of 5 daily tests were administered on study days 1, 2, 3, 5 and 7 up to 1 hour after test substrate administration. Patients were contacted 21 days following study enrollment to determine vital status and to check for the development of serious adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percent Dose Recovery 20 (cPDR20) Value</title>
          <description>The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21.</description>
          <population>Eligible patients enrolled into the study with the initial 13C-MBT conducted on Day 1 or Day 2, and 21 day outcome.</population>
          <units>percentage per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 or 2 MBT/transplant free survival at Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 or 2 MBT &amp; Day 21 non-TFS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAE), suspected adverse reactions (SAR) and unanticipated adverse device effects (UADE) were collected from the initiation of the first MBT through study completion (e.g. Day 21, death, liver transplant or withdrawal of consent). Non-serious adverse events (AE) and adverse device effects (ADE) were collected from from the initiation of the first MBT through Day 7.</time_frame>
      <desc>ADEs caused by insufficiencies/inadequacies in instructions for use, deployment, implantation, installation, operation, investigational medical device malfunction, and event as a result of user error or intentional misuse. UADEs caused by/associated with a device, if effect, problem, or death was not previously identified in nature, severity, or degree of incidence in investigational plan/application on health/safety; life-threatening; or problem related to subject rights, safety, or welfare.</desc>
      <group_list>
        <group group_id="E1">
          <title>13C-Methacetin Breath Test (MBT)</title>
          <description>For each MBT, a baseline measurement was taken for up to 15 minutes using a nasal cannula retrieval device for non-intubated patients or an airway adapter connection to the endotracheal tube of intubated patients that was connected to the Breath ID® MCS device. After completion of the baseline segment, one 75 mg dose of 13C-Methacetin (test substrate) mixed into 150 ml of water was orally ingested by non-intubated patients or administered via nasoenteric tube to intubated patients. The BreathID® MCS device measured expired 13CO2 over a period of up to 60 minutes. A maximum of 5 daily tests were administered on study days 1, 2, 3, 5 and 7 up to 1 hour after test substrate administration. Patients were contacted 21 days following study enrollment to determine vital status and to check for the development of serious adverse events.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment goal of 200 patients not met due to challenges including multiple concomitant contraindicated meds, fasting requirement, establishing rapport with patients' family members due to sudden nature of illness and concerns for liver transplant</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William M. Lee, MD</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>(214) 645-6110</phone>
      <email>William.Lee@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

